Retinalamin
Retina polypeptide complex — a bovine retinal extract given by injection. NOT tretinoin
Retinalamin (Retina polypeptide complex — a bovine retinal extract given by injection. NOT tretinoin) is a longevity & bioregulators research compound. A polypeptide complex extracted from cattle retina and given by injection — intramuscular, or beside the eye by the retrobulbar route. It is the injectable sibling of the eye cytamin, and it is the member of the Khavinson organ-extract family with the largest human literature, essentially all of it Russian and essentially all of it in glaucoma and diabetic retinopathy. The proposed mechanism is the class one: peptide fragments acting on retinal cell proliferation and differentiation. No composition has been published, so there is no named active substance to attach a mechanism to.
Retinalamin quick facts
| Route | IM |
| Frequency | 1x Daily in the published courses · Daily during a course |
| Half-life | Not characterized — no analytical method for this preparation has been published |
| Forms | Injectable |
| Evidence level | A registered medicine in Russia with a substantial Russian clinical literature. The one animal study of it that resolves in English found no neuroprotective effect. |
This is not tretinoin, and the confusion is worth naming because an automated catalog match made it here first: tretinoin is all-trans retinoic acid, a small molecule with an FDA label; this is an undefined bovine retinal extract in a vial. What makes the page worth having is that its own school published the negative result. A 2021 experiment in thirty-six rabbits, in a Russian ophthalmology journal, looked for functional and structural evidence of protection against light-induced retinal damage and reported finding none. The human literature that reports benefit is unmasked, single-country and built on surrogate endpoints.
How Retinalamin works
A polypeptide complex extracted from cattle retina and given by injection — intramuscular, or beside the eye by the retrobulbar route. It is the injectable sibling of the eye cytamin, and it is the member of the Khavinson organ-extract family with the largest human literature, essentially all of it Russian and essentially all of it in glaucoma and diabetic retinopathy. The proposed mechanism is the class one: peptide fragments acting on retinal cell proliferation and differentiation. No composition has been published, so there is no named active substance to attach a mechanism to.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Retinalamin
Buy Retinalamin at RUPharma →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Retinalamin
Graded by what exists behind each claim.
✅ Clinically validated
- The largest human literature of any product in the Khavinson organ-extract family, and all of it Russian: glaucomatous optic neuropathy (Makashova 2014), retinal abiotrophy (Khvatova 2005), and diabetic retinopathy monitored by optical coherence tomography (Malakhova 2024).
- The largest single study is about delivery, and its result is awkward: across 498 patients with open-angle glaucoma, intramuscular, retrobulbar and combined administration were comparable (Erichev 2020). If injecting behind the eye is no better than injecting into muscle, the effect being measured is not coming from local delivery.
- Every one of those studies is unmasked, single-country and built on surrogate endpoints, without independent replication outside the region.
📊 Correlative data
- The negative result comes from the drug's own country. In 36 rabbits with photochemical retinal damage, no significant functional or morphological evidence of neuroprotection by Retinalamin was found (Suetov 2021).
- At cell level the school reports inductive activity of retinal peptides (Khavinson 2002) and therapeutic sensitivity of retinal ganglion cells — the cells that die in glaucoma — to a targeted peptide bioregulator in culture (Avetisov 2019).
🧪 Theoretical / extrapolated
- It is not tretinoin. Tretinoin is all-trans retinoic acid with an FDA label; this is an undefined bovine retina polypeptide complex given by injection. An automated catalog match put the two together before a person looked.
- No composition has been published — no sequence, no molecular weight distribution, no assay — so there is no named active substance for a mechanism to belong to.
- It is the one product in this family whose route needs no defending: injecting removes the gut-wall objection that every cytamin tablet has to answer.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Retinalamin actually does
First, the correction, because a catalog tool got this wrong. Retinalamin is not tretinoin. Tretinoin is all-trans retinoic acid: one small molecule, a defined structure, an FDA label, and a mechanism at nuclear retinoic acid receptors. Retinalamin is an undefined polypeptide complex extracted from cattle retina and given by injection. The two share five letters and nothing else, and an automated name match put them together before a person looked.
What it is, and where it sits in this family. A 5 mg lyophilized vial, ten to a pack at $240, from the same Khavinson organ-extract school as the cytamin tablets — but parenteral rather than oral, which puts it a rung above them on the delivery question and makes it the member of the family with the largest human literature.
The cell-level claim, and it is the school's most specific one. Khavinson 2002 reports inductive activity of retinal peptides; Avetisov 2019 evaluates the therapeutic sensitivity of retinal ganglion cells to a targeted peptide bioregulator in culture. Naming the cell type matters, because retinal ganglion cells are the cells that die in glaucoma, and a claim aimed at a named cell population is testable in a way a claim about tissue support is not.
What is missing from the mechanism, stated plainly. No composition has been published: no peptide sequence, no molecular weight distribution, no assay. So there is no named active substance for the mechanism to belong to, and the sentence peptide bioregulator describes an extraction process rather than a molecule. Everything downstream of that inherits the problem.
Cell, rodent, human — and where it stops
The negative result comes from the drug's own country and it is the most important thing on this page. Suetov 2021 used 36 rabbits in an experimental model of photochemical damage to the retina, looked for functional and morphological evidence of retinoprotection, and reported: no significant functional and morphological evidence of neuroprotective effects of Retinalamin were found. Published in the Russian ophthalmology journal that carries most of this drug's positive literature. A field that publishes its own null result is behaving properly, and a reader weighing this drug should weigh that finding first.
The human literature is large, real, and built on a design that cannot exclude expectation. Makashova 2014 reports application in glaucomatous optic neuropathy; Khvatova 2005 reports polypeptide bioregulators in retinal abiotrophy; Malakhova 2024 is a 2024 study using objective structural and functional monitoring with optical coherence tomography in diabetic retinopathy. That last one is the strongest of the group precisely because it substitutes an instrument for an impression.
The delivery study is the largest number in the file, and it answers a different question than it appears to. Erichev 2020 compared administration routes in 498 patients with open-angle glaucoma — intramuscular, retrobulbar, and combined — and found them comparable, concluding the drug is most effective in initial and moderate stages. Read that carefully: if injecting the material directly behind the eye is no better than injecting it into a muscle in the buttock, then either the route does not matter or the effect being measured is not coming from local delivery.
What is missing from all of it. These are unmasked, single-country studies using surrogate endpoints, without an independent replication outside the region and without a registered protocol a reader can check against the published result. That is a description of the evidence rather than a verdict on the drug, and it is the description a reader needs in order to weigh it.
Retinalamin pharmacokinetics — how much of it actually gets in
What degrades it. A polypeptide complex given by injection meets plasma and tissue peptidases immediately: aminopeptidases and endopeptidases cleave peptides in circulation on a timescale of minutes, and the fragments are cleared renally. That is the general fate of injected peptide material and there is no published reason to think this preparation escapes it.
Why there is no oral version, and why that is the honest argument for the injection. An oral form would face the gut wall and first-pass metabolism, which is where every tablet in this family loses its case. Injecting removes that objection entirely. It is the one product in the Khavinson catalog whose route does not have to be argued for, and the cytamin tablets sold beside it do not have that advantage.
The number nobody has measured, and the number that stands in for it. No plasma concentration, no ocular tissue level and no half-life has been published for this preparation, because no analytical method for it has been published — there is no analyte to follow. The one quantitative statement available about delivery is Erichev 2020: across 498 patients, retrobulbar injection was not superior to intramuscular. In a drug delivered to a compartment behind a blood-retinal barrier, that is a surprising result and it deserves to be treated as a finding rather than a convenience.
What the dosing schedule implies. A pack of ten 5 mg vials matches the five-to-ten-day courses the Russian literature uses, repeated at intervals. A course-based schedule for a peptide with minutes-scale plasma survival implies that any effect is a consequence of repeated brief exposures rather than of an accumulated level — which is a testable claim that nobody has tested.
What would have to be true, and how you would know it was not
The read-out here is ophthalmic rather than hematologic, so the falsification is instrumental and specific.
what to watch. Three measurements, in increasing order of how hard they are to fool. Best-corrected visual acuity, which is quick and highly learnable. Standard automated perimetry — the visual field — which is the endpoint glaucoma is managed on and which has substantial test-retest variability. And optical coherence tomography measurement of retinal nerve fiber layer and ganglion cell complex thickness, which is structural, quantitative and the endpoint Malakhova 2024 chose for exactly that reason.
how long before it means anything. Structural change in glaucoma is measured over years, not courses. Nerve fiber layer thinning proceeds at a fraction of a micrometer a year in most eyes, which is why glaucoma trials run for years and why a before-and-after across one ten-vial course cannot detect a real structural effect. Anything that changes in ten days is function or measurement noise, not structure.
what will fool you. Four things, and they are the reason unmasked studies of this drug are hard to weigh. Perimetry has a large learning effect, so a second field test is usually better than the first regardless of treatment. Visual acuity varies with refraction, tear film and lighting. Glaucoma is usually treated concurrently with pressure-lowering drops, and pressure is what actually drives progression. And an injected course delivered by a clinician carries the strongest expectation effect available in medicine.
Against the product, from its own literature. Suetov 2021 looked for retinoprotection in a controlled animal model and found none. The prediction that follows is that a masked, controlled human trial with a structural endpoint would also find none, and that prediction is the one the existing human literature cannot address because none of it is masked.
What nobody has tested yet
No masked randomized controlled trial exists. Every human study of this drug that a search returns is unmasked or uncontrolled. A sham-injection design in glaucoma with an optical coherence tomography endpoint is entirely feasible and has never been published for it.
No composition has been published. Mass spectrometry on the contents of one vial would give the peptide profile and molecular weight distribution, and would let anybody ask whether the retinal extract differs from the other organ extracts in this catalog at all.
Nobody has reconciled the negative animal result with the positive clinical reports. Suetov 2021 and Makashova 2014 point in opposite directions and neither cites a mechanism that would explain the difference. Reconciling them is normally the job of a better-designed human study, and that study has not been done.
Extrapolation, labeled as such. If the effect were local, retrobulbar delivery should beat intramuscular. Erichev 2020 reports they are comparable across 498 patients, which points toward either a systemic mechanism or no mechanism. Distinguishing those two requires a placebo arm, and that is the arm this entire literature does not have.
Retinalamin — its own safety story, not its class's
Three things specific to an injected bovine retinal extract.
The route carries hazards the material does not. Retrobulbar injection places a needle into the orbit, and its recognized complications include retrobulbar hemorrhage, globe perforation and optic nerve injury. Those are procedural risks that exist regardless of what is in the syringe. Erichev 2020 found retrobulbar delivery no better than intramuscular across 498 patients, which means the extra risk of the orbital route buys nothing that study could measure.
Injected animal protein is an immunological question, and it is unanswered here. Repeated parenteral administration of a foreign protein preparation is the classic setting for sensitization, and no published study of this product reports immunogenicity testing, antibody formation or hypersensitivity rates. Bovine central nervous system-derived material also sits inside the specified-risk-material frameworks that exist because of transmissible spongiform encephalopathy, and no vendor publishes source species, country or animal age.
The harm most likely to happen is a delay. Glaucoma and diabetic retinopathy are managed with treatments that have controlled evidence — pressure reduction, laser, anti-VEGF injection, glycemic control. Substituting a course of this for any of them is a way of losing vision slowly and irreversibly while feeling treated. Sudden vision loss, new floaters, flashing lights or eye pain need same-day assessment. Nothing on this page is a diagnosis or a substitute for ophthalmic care.
Sources read for this page
- Suetov AA. Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas. Vestnik Oftalmologii 2021 [Russian] · PMID 34726859
- Erichev VP, Lovpache DN, Yaremenko TV. [Peptide bioregulators: delivery and efficacy]. Vestnik Oftalmologii 2020 [Russian] · PMID 32366071
- Makashova NV, Vasil'eva AE, Morozova NE, Ronzina IA. Application of Retinalamin for the treatment of glaucomatous optic neuropathy. Vestnik Oftalmologii 2014 [Russian] · PMID 25306728
- Khavinson VKh. Inductive activity of retinal peptides. Bulletin of Experimental Biology and Medicine 2002 · PMID 12802458
- Avetisov SE. Evaluation of therapeutic sensitivity of retinal ganglion cells to targeted peptide bioregulator in culture. Vestnik Oftalmologii 2019 [Russian] · PMID 30830079
- Malakhova AI. Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy. Vestnik Oftalmologii 2024 [Russian] · PMID 39569781
- Khvatova AV, Khlebnikova OV, Meshkova GI, Tarasenkov AO, Shchuvatova EL, Stromova OV. Polypeptide bioregulators in the treatment of different-type abiotrophy of the retina. Vestnik Oftalmologii 2005 [Russian] · PMID 15881150
Retinalamin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Retinalamin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Retinalamin moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Retinalamin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Retinalamin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Retinalamin — frequently asked questions
What is Retinalamin?
Retinalamin (Retina polypeptide complex — a bovine retinal extract given by injection. NOT tretinoin) is a longevity & bioregulators research compound. A polypeptide complex extracted from cattle retina and given by injection — intramuscular, or beside the eye by the retrobulbar route. It is the injectable sibling of the eye cytamin, and it is the member of the Khavinson organ-extract family with the largest human literature, essentially all of it Russian and essentially all of it in glaucoma and diabetic retinopathy. The proposed mechanism is the class one: peptide fragments acting on retinal cell proliferation and differentiation. No composition has been published, so there is no named active substance to attach a mechanism to.
Where can I find Retinalamin dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Retinalamin protocol are available to members inside Skool. This public page covers what Retinalamin is, how it works and the evidence.
What is the half-life of Retinalamin?
Retinalamin has an approximate half-life of Not characterized — no analytical method for this preparation has been published, which is part of what determines how often it's dosed.
What's the evidence behind Retinalamin?
Current evidence level: A registered medicine in Russia with a substantial Russian clinical literature. The one animal study of it that resolves in English found no neuroprotective effect.. Retinalamin is offered for research purposes only and is not an approved medicine.
What Retinalamin is used for
Retinalamin appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.